CLSD250117C5000
- 0.06
- 0.000.00%
Clearside Biomedical Newsroom
Clearside Biomedical Announces Publication of Critical Insights Into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
Clearside Biomedical Highlights Advancements in Drug Delivery
Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now
Clearside Biomedical Is Maintained at Buy by Chardan Capital
JonesTrading Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $6
Promising Outlook for Clearside Biomedical: Buy Rating Backed by Strong Phase 2b ODYSSEY Trial Data and Robust Cash Position
Oppenheimer Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $5
Needham Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $6
Needham Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Clearside Biomedical Analyst Ratings
Clearside Biomedical | 10-Q: Q3 2024 Earnings Report
Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript Summary
Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates
Express News | Clearside Biomedical Inc: Believes It Will Have Sufficient Resources to Fund Its Planned Operations Into Q3 of 2025
Clearside Biomedical | 8-K: Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Express News | Clearside Biomedical Q3 EPS USD -0.1
Clearside Biomedical 3Q Loss/Shr 10c >CLSD
Here Are the Major Earnings After the Close Today
Even After Rising 13% This Past Week, Clearside Biomedical (NASDAQ:CLSD) Shareholders Are Still Down 77% Over the Past Three Years